Identification of Kininogen-1 as a Serum Biomarker for the Early Detection of Advanced Colorectal Adenoma and Colorectal Cancer

Background Serum markers represent potential tools for the detection of colorectal cancer (CRC). The aim of this study was to obtain proteomic expression profiles and identify serum markers for the early detection of CRC. Methods Proteomic profiles of serum samples collected from 35 healthy volunteers, 35 patients with advanced colorectal adenoma (ACA), and 40 patients with CRC were compared using Clinprot technology. Using enzyme-linked immunosorbent assays (ELISAs), 366 sera samples were additionally analyzed, and immunohistochemistry studies of 400 tissues were used to verify the expression of kininogen-1 and its value in the early detection of CRC. Results Predicting models were established among the three groups, and kininogen-1 was identified as a potential marker for CRC using Clinprot technology. ELISAs also detected significantly higher serum kininogen-1 levels in ACA and CRC patients compared to controls (P<0.05). Furthermore, the area under the receiver operating characteristic curve (AUC) for serum kininogen-1 in the diagnosis of ACA was 0.635 (P = 0.003), and for serum carcinoembryonic antigen (CEA) was 0.453 (P = 0.358). The sensitivity, specificity, and accuracy of serum kininogen-1 for diagnosing Duke’s stage A and B CRC was 70.13%, 65.88%, and 67.90%, respectively, whereas serum CEA was 38.96%, 85.88%, and 63.58%, respectively. Moreover, immunohistochemistry showed that expression of kininogen-1 was significantly higher in CRC and ACA tissues than in normal mucosa (48.39% vs. 15.58% vs. 0%, P<0.05). Conclusions These results suggest that Clinprot technology provides a useful tool for the diagnosis of CRC, and kininogen-1 is a potential serum biomarker for the early detection of advanced colorectal adenoma and CRC.

[1]  Wentao Liu,et al.  Identification of novel serum biomarkers for gastric cancer by magnetic bead. , 2010, Frontiers in bioscience.

[2]  E. Giovannucci,et al.  Family history of colorectal cancer: A determinant of advanced adenoma stage or adenoma multiplicity? , 2009, International journal of cancer.

[3]  T. Tani,et al.  Effect of His-Gly-Lys Motif Derived from Domain 5 of High Molecular Weight Kininogen on Suppression of Cancer Metastasis Both in Vitro and in Vivo* , 2003, Journal of Biological Chemistry.

[4]  F. Chan,et al.  Asia Pacific consensus recommendations for colorectal cancer screening , 2008, Gut.

[5]  W. Grizzle,et al.  Applying Proteomic-Based Biomarker Tools for the Accurate Diagnosis of Pancreatic Cancer , 2008, Journal of Gastrointestinal Surgery.

[6]  R. Pearson.  Low Risk of Colorectal Cancer and Advanced Adenomas More Than 10 Years After Negative Colonoscopy , 2010 .

[7]  O. Hashim,et al.  Expression of high‐abundance proteins in sera of patients with endometrial and cervical cancers: Analysis using 2‐DE with silver staining and lectin detection methods , 2007, Electrophoresis.

[8]  N. Lion,et al.  Proteomics of blood and derived products: what’s next? , 2011, Expert review of proteomics.

[9]  B. Jiang,et al.  Increased Expression of β-Catenin, Phosphorylated Glycogen Synthase Kinase 3β, Cyclin D1, and c-myc in Laterally Spreading Colorectal Tumors , 2009, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[10]  L. Cazares,et al.  Differential Capture of Serum Proteins for Expression Profiling and Biomarker Discovery in Pre‐ and Posttreatment Head and Neck Cancer Samples , 2008, The Laryngoscope.

[11]  An investigation on the nature of the peptide at m/z 904, overexpressed in plasma of patients with colorectal cancer and familial adenomatous polyposis. , 2007, Journal of mass spectrometry : JMS.

[12]  Stefano Ferrero,et al.  Serum biomarkers of renal cell carcinoma assessed using a protein profiling approach based on ClinProt technique. , 2010, Urology.

[13]  K. Matsushita,et al.  Identification of a high molecular weight kininogen fragment as a marker for early gastric cancer by serum proteome analysis , 2011, Journal of Gastroenterology.

[14]  Hanno Langen,et al.  Identification of Nicotinamide N-Methyltransferase as a Novel Serum Tumor Marker for Colorectal Cancer , 2005, Clinical Cancer Research.

[15]  H. Nielsen,et al.  National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. , 2008, Clinical chemistry.

[16]  T. Conrads,et al.  Advances in proximal fluid proteomics for disease biomarker discovery. , 2010, Journal of proteome research.

[17]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[18]  A. Jemal,et al.  Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates , 2010, Cancer.

[19]  Hung-Ming Wang,et al.  Increase diagnostic efficacy by combined use of fingerprint markers in mass spectrometry--plasma peptidomes from nasopharyngeal cancer patients for example. , 2006, Clinical biochemistry.

[20]  R. Colman,et al.  The inhibitory effect of HKa in endothelial cell tube formation is mediated by disrupting the uPA-uPAR complex and inhibiting its signaling and internalization. , 2008, American journal of physiology. Cell physiology.

[21]  E. Mitchell,et al.  Carcinoembryonic Antigen in the Staging and Follow-up of Patients with Colorectal Cancer , 2005, Cancer investigation.

[22]  D. Lieberman,et al.  Accuracy of Screening for Fecal Occult Blood on a Single Stool Sample Obtained by Digital Rectal Examination: A Comparison with Recommended Sampling Practice , 2005, Annals of Internal Medicine.

[23]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[24]  A. Jemal,et al.  Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer , 2014, Cancer.

[25]  D. Ransohoff,et al.  Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. , 2004, The New England journal of medicine.

[26]  R. Colman,et al.  Biologic Activities of the Contact Factors In Vivo , 1999, Thrombosis and Haemostasis.

[27]  M. Tsai,et al.  Salivary zinc finger protein 510 peptide as a novel biomarker for detection of oral squamous cell carcinoma in early stages. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[28]  V. Gnau,et al.  Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. , 2006, Proteomics.

[29]  A. Aasen,et al.  Studies on components of the contact phase system in patients with advanced gastrointestinal cancer , 1990, Cancer.

[30]  Tasneem H. Patwa,et al.  Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. , 2008, Journal of proteome research.

[31]  Cancer,et al.  Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial , 2010, The Lancet.

[32]  G. Yousef,et al.  The new human tissue kallikrein gene family: structure, function, and association to disease. , 2001, Endocrine reviews.

[33]  J. Solassol,et al.  Clinical proteomics and mass spectrometry profiling for cancer detection , 2006, Expert review of proteomics.

[34]  O. Hashim,et al.  Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin , 2010, Proteome Science.